STRI: A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY)

Sponsor
Abbott (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04784208
Collaborator
(none)
232
11
23.4
21.1
0.9

Study Details

Study Description

Brief Summary

Type of Study Questionnaire- Development and validation

Information about the Q'SHY:
  • The Q'SHY- Questionnaire for Screening of Hypothyroidism is a Patient Reported Outcome (PRO) tool to enable screening for Hypothyroidism in the general population.

  • It is a 20-item questionnaire which covers aspects of the symptoms of Hypothyroidism and incorporates the contributory factors from patient history which when combined, provides a robust tool to effectively screen the population.

  • The questionnaire content is being created based on a thorough search for relevant literature and encompasses all important aspects for screening purposes

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Blood test for Thyroid stimulating hormone (TSH)

Detailed Description

Objectives The objectives of the study are as described in the below points.

  1. To develop a questionnaire (Q'SHY) for the identification and screening of subjects with suspected hypothyroidism.

  2. To assess the validity of the designed questionnaire by comparing the outcomes of the responses between General population subjects and treatment naïve subjects group with hypothyroidism.

  3. The study aims to establish a valid questionnaire with a robust sensitivity and specificity to detect signs and symptoms of hypothyroidism.

Inclusion criteria for Subjects The criteria based on which, subjects in each Arm will be chosen to take part in the survey. Arm1: Subjects from the general population who are naïve to their hypothyroid status.

  • Male and female subjects between the age of 18 years and 65 years

  • Willing to sign the Subject Authorization Form (SAF) Arm 2: Subjects who are newly diagnosed patients of Hypothyroidism and are treatment naïve*.

  • Male and female subjects between the ages 18 years and 65 years.

  • Subjects who had symptoms of hypothyroidism were seen by a physician and diagnosed with hypothyroidism after laboratory testing of Thyroid Stimulating Hormone > 4.5 Milli international units per litre(mIU/L) within 2 weeks from the date of the survey

  • Willing to sign the SAF

  • Willing to provide their Thyroid Function Test report that was used to diagnose Hypothyroidism. * Treatment naive diagnosed on basis lab and clinical diagnosis within last 2 weeks

Exclusion criteria for subjects Arm 1: Subjects from the general population who are naïve to their hypothyroid status

  • Individuals less than 18 years of age and more than 65 years of age.

  • Pregnant or lactating females Subjects previously diagnosed with and received treatment for thyroid diseases.

  • Subjects not willing to sign the SAF.

Arm 2: Subjects who are newly diagnosed patients of Hypothyroidism and are treatment naïve

  • Individuals less than 18 years of age and more than 65 years of age.

  • Pregnant or lactating females

  • Subjects previously diagnosed with and received treatment for thyroid diseases.

  • Patients on treatment for Thyroid diseases Subjects not willing to sign the SAF.

The above-mentioned criteria will be applicable to both Face validation and Pilot survey.

  1. Subjects are divided into 2 arms, with 100 subjects in each arm.

  2. Phase -1

  • Arm 1: Sixteen subjects from the general population who are naïve to their hypothyroid status with equal distribution of males and females.

  • Arm 2: Sixteen subjects who are newly diagnosed patients of Hypothyroidism are treatment naïve with equal distribution of males and females

  1. Phase -2
  • Arm 1: One hundred subjects from the general population who are naïve to their hypothyroid status with equal distribution of males and females

  • Arm 2: One hundred subjects who are newly diagnosed patients of Hypothyroidism are treatment naïve with equal distribution of males and females

Study Design

Study Type:
Observational
Anticipated Enrollment :
232 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY)
Actual Study Start Date :
Jan 18, 2021
Anticipated Primary Completion Date :
Jul 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Arm 1-Healthy Volunteers

Arm 1: Subjects from the general population who are naïve to their hypothyroid status. The Subjects will be randomly selected and will be equally stratified between genders and socio-economics statuses from places where groups of general populations are located

Diagnostic Test: Blood test for Thyroid stimulating hormone (TSH)
Blood test for Thyroid stimulating hormone (TSH)

Arm 2- Hypothyroid treatment naïve patients

The subjects will be identified and selected from clinical settings such as hospitals, clinics and certified laboratories.

Outcome Measures

Primary Outcome Measures

  1. To be able to develop a questionnaire (Q'SHY) for the identification and screening of subjects with suspected hypothyroidism [through out the study upto 1 year]

    The aim is to develop a questionnaire considering literature review for symptoms selection, medical review of symptoms appropriateness, assigning weightage & questionnaire construction followed by expert review to construct a questionnaire

  2. To be able to assess the validity of the designed questionnaire by comparing the outcomes of the responses between General population subjects and treatment naïve subjects group with hypothyroidism. [through out the study upto 1 year]

    Through this study, we want to assess the validity of the questionnaire after receiving and comparing responses received from healthy volunteers and treatment naïve subjects with hypothyroidism through out the study we will have face validation of survey questionnaire - Face validation of survey questionnaire in hypothyroidism naïve and treatment naïve patients of hypothyroidism, revision of questionnaire if required after expert review of validation results

  3. To be able to establish a valid questionnaire with a robust sensitivity and specificity to detect signs and symptoms of hypothyroidism [through out the study upto 1 year]

    in this, Pilot survey in hypothyroidism naïve and treatment naïve patients of hypothyroidism will be conducted and data will be analyzed and used to establish validation.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • The criteria based on which, subjects in each Arm will be chosen to take part in the survey. Arm 1: Subjects from the general population who are naïve to their hypothyroid status.

  • Male and female subjects between the age of 18 years and 65 years

  • Willing to sign the Subject Authorization Form (SAF) Arm 2: Subjects who are newly diagnosed patients of Hypothyroidism and are treatment naïve*.

  • Male and female subjects between the ages 18 years and 65 years.

  • Subjects who had symptoms of hypothyroidism, were seen by a physician and diagnosed with hypothyroidism after laboratory testing of TSH > 4.5 mIU/L within 2 weeks from the date of survey

  • Willing to sign the SAF

  • Willing to provide their Thyroid Function Test report that was used to diagnose Hypothyroidism. * Treatment naive diagnosed on basis lab and clinical diagnosis within last 2 weeks

Exclusion Criteria:
  • Arm 1: Subjects from the general population who are naïve to their hypothyroid status

  • Individuals less than 18 years of age and more than 65 years of age.

  • Pregnant or lactating females

  • Subjects previously diagnosed with and received treatment for thyroid diseases.

  • Subjects not willing to sign the SAF. Arm 2: Subjects who are newly diagnosed patients of Hypothyroidism and are treatment naïve

  • Individuals less than 18 years of age and more than 65 years of age.

  • Pregnant or lactating females

  • Subjects previously diagnosed with and received treatment for thyroid diseases.

  • Patients on treatment for Thyroid diseases Subjects not willing to sign the SAF.

The above-mentioned criteria will be applicable to both Face validation and Pilot survey.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Diabecare Mumbai Maharashtra India 400706
2 Center for Diabetes and Endocrine care Bangalore India 560043
3 Apollo Excelcare Hospital Guwahati India 781033
4 Care Outpatient Centre Hyderabad India 500034
5 FS Endocrine and Diabetic Centre Hyderabad India 500059
6 Dr. MV Rama Mohan, MD, DM Hyderabad India
7 Diabetes Thyroid Endocrine Center Jaipur India 302006
8 Healthy Lifestyle Clinic Kolkata India 700014
9 Ananda Clinic Kolkata India 700034
10 Khandelwal Diabetes Thyroid & Endocrinology Clinic New Delhi India 110063
11 Chellaram Diabetes Institute Pune India 411021

Sponsors and Collaborators

  • Abbott

Investigators

  • Study Director: Shivani Acharya, Abbott

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Abbott
ClinicalTrials.gov Identifier:
NCT04784208
Other Study ID Numbers:
  • EPIDI077
First Posted:
Mar 5, 2021
Last Update Posted:
Jul 13, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 13, 2022